Search results for " Macro"

showing 10 items of 522 documents

Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers

2016

Background: Adult-onset Still's disease (AOSD) is rare inflammatory disease of unknown etiology that usually affects young adults. The more common clinical manifestations are spiking fevers, arthritis, evanescent rash, elevated liver enzymes, lymphadenopathy, hepatosplenomegaly, and serositis. The multi-visceral involvement of the disease and the different complications, such as macrophage activation syndrome, may strongly decrease the life expectancy of AOSD patients. Methods: This study aimed to identify the positive and negative features correlated with the outcome of patients. A retrospective analysis of AOSD patients prospectively admitted to three rheumatologic centers was performed t…

AdultMale0301 basic medicinemedicine.medical_specialtyPrognosiHepatosplenomegalyArthritisDiseaseAdult-onset Still's diseaseYoung Adult03 medical and health sciencesSystemic score0302 clinical medicineRetrospective StudieInternal medicinemedicineHumansYoung adultRetrospective StudiesAdult-onset Still’s diseaseMedicine(all)030203 arthritis & rheumatologyPrognostic factorbusiness.industryMedicine (all)BiomarkerGeneral MedicineMiddle AgedPrognosismedicine.diseaseRashSurgerySettore MED/16 - Reumatologia030104 developmental biologyMacrophage activation syndromeMacrophage activation syndromeEtiologyAdult-onset Still’s disease; Macrophage activation syndrome; Prognostic factor; Systemic scoreFemalemedicine.symptombusinessStill's Disease Adult-OnsetSerositisBiomarkersHumanResearch ArticleBMC Medicine
researchProduct

Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical hodgkin lymphoma and correlation with early FDG-PET a…

2017

In Hodgkin Lymphoma (HL), about 20% of patients still have relapsed/refractory disease and late toxic effects rate continue to rise with time. 'Early FDG-PET' and tissue macrophage infiltration (TAM) emerged as powerful prognostic predictors. The primary endpoint was to investigate the prognostic role of both early FDG-PET and TAM; the secondary endpoint was to test if early FDG-PET positivity could correlate with high TAM score. A cohort of 200 HL patients was analysed. Induction treatment plan consisted of two to six courses of ABVD and, if indicated, involved field radiation therapy. All patients repeated CT scan and FDG-PET after two cycles and after the completion of therapy. TAM in di…

AdultMaleAdolescentHodgkin’s lymphomaMacrophagePrognosiAntigens Differentiation MyelomonocyticVinblastineDisease-Free SurvivalCohort StudiesBleomycinYoung AdultAntigens CDFluorodeoxyglucose F18RecurrencePositron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsHumansCD68AgedAged 80 and overHodgkin's lymphomahematologyMacrophagesCD68; Hodgkin's lymphoma; macrophages; PET; prognosis; hematology; oncology; cancer researchAntibodies MonoclonalMiddle AgedPrognosisHodgkin DiseaseImmunohistochemistryDacarbazineTreatment OutcomePETDoxorubicinPositron-Emission Tomographyoncologycancer researchFemaleNeoplasm Recurrence LocalFollow-Up Studies
researchProduct

The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammatio…

2013

Macrophages reside in tissues infiltrated by chronic lymphocytic leukemia B cells and the extent of infiltration is associated with adverse prognostic factors. We studied blood monocyte population by flow cytometry and whole-genome microarrays. A mixed lymphocyte reaction was performed to evaluate proliferation of T cells in contact with monocytes from patients and normal donors. Migration and gene modulation in normal monocytes cultured with CLL cells were also evaluated. The absolute number of monocytes increased in chronic lymphocytic leukemia patients compared to the number in normal controls (792 +/- 86 cells/mu L versus 485 +/- 46 cells/mL, P=0.003). Higher numbers of non-classical CD…

AdultMaleCD14Chronic lymphocytic leukemiaPhagocytosisPopulationDown-RegulationInflammationMICROENVIRONMENTCD16BiologyTUMOR-ASSOCIATED MACROPHAGES; TIE2-EXPRESSING MONOCYTES; MICROENVIRONMENT; CLLMonocytesImmune systemPhagocytosismedicineHumanseducationCells CulturedAgedAged 80 and overInflammationeducation.field_of_studyMonocyteGene Expression ProfilingHematologyMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-CellTIE2-EXPRESSING MONOCYTESGene Expression Regulation NeoplasticChronic Lymphocytic Leukemia; Monocyte; microenvironmentTUMOR-ASSOCIATED MACROPHAGESmedicine.anatomical_structureImmunologyFemalemedicine.symptomLymphocyte Culture Test MixedOriginal Articles and Brief ReportsCLLHaematologica
researchProduct

Sister chromatid exchange in Waldenström's macroglobulinemia

1993

Results on sister chromatid exchange (SCE) frequency and interchromosomal distribution in bone marrow and peripheral blood cultures from patients with Waldenström's macroglobulinemia are reported. PHA-stimulated bone marrow cultures showed increased SCE frequencies in all 12 patients examined. The increase was particularly high in two cases (17.07 and 16.77 SCE/cell, respectively) and, in one of them, a very high SCE level was found in PHA-stimulated peripheral blood culture (40.81 SCE/cell). In LPS-stimulated cultures, increased SCE levels were observed in some patients. Comparison between SCE frequency in bone marrow cell cultures with either mitogen showed a significant increase in PHA-s…

AdultMaleCancer ResearchG chromosomeCellSister chromatid exchangeBiologyGeneticsmedicineHumansPooled dataMolecular BiologyAgedCell CycleMacroglobulinemiaWaldenstrom macroglobulinemiaMiddle AgedCell cyclemedicine.diseaseMolecular biologySettore BIO/18 - Geneticamedicine.anatomical_structureImmunologySister chromatid exchanges Waldenstrom's macroglobulinemiaFemaleBone marrowWaldenstrom MacroglobulinemiaSister Chromatid ExchangeCancer Genetics and Cytogenetics
researchProduct

Chromosomal abnormalities in Waldenström's macroglobulinemia

1992

We report the results of cytogenetic studies of direct bone marrow (BM) preparations and of short-term BM and peripheral blood (PB) cultures from 17 patients with Waldenström's macroglobulinemia. We noted clonal chromosome changes in 10 patients. Abnormalities affected chromosomes X, Y, 2, 4, 5, 15, 16, 18, 19, 20, 21, and 22; in particular, chromosomes 2, 4, and 5 were involved in structural changes: a homogeneously staining region [hsr(2)], a der(4)t(4;?)(q32;?), and a 5q+. The other chromosomes were involved in numerical abnormalities, such as pseudodiploidy (a 46,X,-X,+15 clone), loss of chromosome Y, and monosomy of chromosomes 16, 18, 19, 20, 21, and 22. Nonclonal chromosome rearrange…

AdultMaleCancer Researchmedicine.medical_specialtyMonosomyClone (cell biology)Chromosome rearrangements Waldenström's macroglobulinemiaBiologyGeneticsmedicineHumanseducationMolecular BiologyHomogeneously Staining RegionAgedGeneticsAged 80 and overChromosome Aberrationseducation.field_of_studyCytogeneticsMacroglobulinemiaWaldenstrom macroglobulinemiaChromosomeKaryotypeMiddle Agedmedicine.diseaseMolecular biologySettore BIO/18 - GeneticaChromosomes Human Pair 2FemaleWaldenstrom Macroglobulinemia
researchProduct

Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor.

1989

The in vivo effect of yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) was investigated in 30 patients with advanced malignancy in a phase Ib trial. Patients were treated at four different dose levels (120 to 1,000 micrograms/m2/d) by either daily intravenous (IV) bolus injection or 24-hour continuous infusion. Administration of rh GM-CSF resulted in a broad spectrum of dose- and schedule-dependent hematopoietic effects. Sustained infusion of rh GM-CSF elicited a maximum 17-fold average peak increase of the total WBC count with mainly neutrophils, eosinophils, and monocytes accounting for this rise, and increases in bone marrow cellularity with a…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentMicrogramMalignancyDrug Administration ScheduleLeukocyte CountColony-Stimulating FactorsIn vivoBone MarrowInternal medicineNeoplasmsmedicineHumansPlateletLeukocytosisGrowth SubstancesInfusions IntravenousAgedbusiness.industryPlatelet CountGranulocyte-Macrophage Colony-Stimulating FactorMiddle Agedmedicine.diseaseRecombinant ProteinsHematopoiesisHaematopoiesisEndocrinologyGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureOncologyImmunologyInjections IntravenousDrug EvaluationFemalemedicine.symptombusinessmedicine.drugJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

CONSISTENT BONE MARROW-DERIVED CELL MOBILIZATION FOLLOWING REPEATED SHORT COURSES OF GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH AMYOTROPH…

2009

Background and aims. The aim of this study was to evaluate and characterize the feasibility and safety of bone marrow-derived cell (BMC) mobilization following repeated courses of granulocyte-colony stimulating factor (G-CSF) in patients with amyotrophic lateral sclerosis (ALS). Methods. Between January 2006 and March 2007, 26 ALS patients entered a multicenter trial that included four courses of BMC mobilization at 3-month intervals. In each course, G-CSF (5 mu g/kg b.i.d.) was administered for four consecutive days; 18% mannitol was also given. Mobilization was monitored by flow cytometry analysis of circulating CD34(+) cells and by in vitro colony assay for clonogenic progenitors. Co-exp…

AdultMaleCancer Researchmedicine.medical_specialtySLa - trial clinico - C-GSFImmunologyAntigens CD34Bone Marrow CellsDrug Administration ScheduleColony-Forming Units AssayCell MovementInternal medicineMulticenter trialmedicineImmunology and AllergyHumansCell LineageProspective StudiesAmyotrophic lateral sclerosisProspective cohort studyGenetics (clinical)Hematopoietic Stem Cell MobilizationNeuronsTransplantationMobilizationbusiness.industryStem CellsAmyotrophic Lateral SclerosisGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationCell BiologyMiddle Agedmedicine.diseaseHematopoietic Stem CellsBone Marrow-Derived CellHematopoietic Stem Cell MobilizationSurgeryGranulocyte colony-stimulating factorNerve RegenerationSettore MED/26 - NEUROLOGIAGranulocyte macrophage colony-stimulating factorTreatment OutcomeOncologyBiological MarkersFemalebusinessNeurogliaBiomarkersmedicine.drug
researchProduct

In Lysinuric Protein Intolerance system y+L activity is defective in monocytes and in GM-CSF-differentiated macrophages

2010

Abstract Background In the recessive aminoaciduria Lysinuric Protein Intolerance (LPI), mutations of SLC7A7/y+LAT1 impair system y+L transport activity for cationic amino acids. A severe complication of LPI is a form of Pulmonary Alveolar Proteinosis (PAP), in which alveolar spaces are filled with lipoproteinaceous material because of the impaired surfactant clearance by resident macrophages. The pathogenesis of LPI-associated PAP remains still obscure. The present study investigates for the first time the expression and function of y+LAT1 in monocytes and macrophages isolated from a patient affected by LPI-associated PAP. A comparison with mesenchymal cells from the same subject has been a…

AdultMaleCellular differentiationlcsh:MedicinePulmonary Alveolar ProteinosisBiologyMonocytesPathogenesisYoung AdultMacrophages AlveolarmedicineHumansGenetics(clinical)Pharmacology (medical)Amino Acid Metabolism Inborn ErrorsCells CulturedGenetics (clinical)Medicine(all)chemistry.chemical_classificationResearchFusion Regulatory Protein 1 Light ChainsLysinelcsh:RMesenchymal stem cellAmino Acid Transport System y+LGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationGeneral Medicinemedicine.diseaseLysinuric protein intoleranceMolecular biologyAmino acidGranulocyte macrophage colony-stimulating factorchemistryAminoaciduriaImmunologyPulmonary alveolar proteinosismedicine.drugOrphanet Journal of Rare Diseases
researchProduct

Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project

2014

Background: Non-Hodgkin lymphoma (NHL), the most common hematologic malignancy, consists of numerous subtypes. The etiology of NHL is incompletely understood, and increasing evidence suggests that risk factors may vary by NHL subtype. However, small numbers of cases have made investigation of subtype-specific risks challenging. The International Lymphoma Epidemiology Consortium therefore undertook the NHL Subtypes Project, an international collaborative effort to investigate the etiologies of NHL subtypes. This article describes in detail the project rationale and design. Methods: We pooled individual-level data from 20 case-control studies (17 471 NHL cases, 23 096 controls) from North Ame…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyAdolescentChronic lymphocytic leukemiaFollicular lymphomaNon-Hodgkin lymphoma (NHL)ArticleLymphoplasmacytic LymphomaYoung AdultRisk Factorsimmune system diseaseshemic and lymphatic diseasesInternal medicineEpidemiology of cancerPrevalencemedicineHumansAgedAged 80 and overMycosis fungoidesbusiness.industryLymphoma Non-HodgkinAustraliaWaldenstrom macroglobulinemiaGeneral MedicineMiddle Agedmedicine.diseaseNon-Hodgkin's lymphomaEuropeOncologyCase-Control StudiesEpidemiologic Research DesignNorth AmericaImmunologyInternational Lymphoma Epidemiology Consortiumhematologic malignancyFemaleMantle cell lymphomabusinessJNCI Monographs
researchProduct

Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century

2017

Population-level survival has increased for a number of hematologic malignancies.[1][1]–[3][2] Multiple myeloma, in particular, has seen improved survival both in clinical trials[4][3]–[8][4] and on the population level.[3][2],[9][5]–[11][6] However, it is not known whether the changes in

AdultMalePathologymedicine.medical_specialtyAdolescentPopulationImproved survivalLymphoplasmacytic Lymphoma03 medical and health sciencesYoung Adult0302 clinical medicineGermanymedicineHumansRegistrieseducationOnline Only ArticlesMultiple myelomaAgededucation.field_of_studybusiness.industryHematologyMiddle Agedmedicine.diseaseUnited StatesSurvival Rate030220 oncology & carcinogenesisPopulation SurveillanceFemaleWaldenstrom MacroglobulinemiabusinessSolitary plasmacytoma030215 immunologyPlasmacytomaSEER Program
researchProduct